Headquartered in Chicago, Illinois, Meitheal brings to market innovative and impactful biopharmaceutical products with its global strategic partners.
Learn more about what Meitheal Pharmaceuticals is doing to deliver on its vision of Healthcare Solutions within reach.
Watch VideoEvolving a Foundation that Has Proven to Deliver
Meitheal is building on its success in generic injectables as it expands into both the branded and biosimilar markets.
2017-2019
Foundation
- $95M investment
- $45M in R&D
- 19 marketed products
2020-2023
Expansion
- Profitability achieved
- $231M in revenue
- 59 marketed products
2023-2026
Transformation
-
Acquired YUSIMRY®
(adalimumab-aqvh) - $385M in revenue
- 84 marketed products
2026+
Today
- 460+ active contracts
- 96,000+ customers served
Reliable supply is expected.
Consistent production and fulfillment make it possible.
Units Shipped
Supply Fill Rate
-
98%2023
-
99%2024
-
99%2025
Our Pipeline
Meitheal is prioritizing a portfolio strategy centered on standards of care to ensure the ongoing availability of important biologics.
- All Products
- Anti-Infective
- Diabetes
- Fertility
- Immunology & Inflammation
- Oncology
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
- Submission
- Approved
Brands
| Drug Name | Therapeutic Area | Type | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Submission | Approved |
|---|---|---|---|---|---|---|---|---|---|
| XENLETA® (lefamulin) | Anti-Infective | Small Molecule | |||||||
| Contepo™ (fosfomycin) for injection | Anti-Infective | Small Molecule | |||||||
| XTMAB-16 | Immunology & Inflammation | Biologic | |||||||
Biologics
| Drug Name | Therapeutic Area | Type | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Submission | Approved |
|---|---|---|---|---|---|---|---|---|---|
| Denosumab | Immunology & Inflammation | Biosimilar | |||||||
| YUSIMRY HC | Immunology & Inflammation | Biosimilar | |||||||
| Filgrastim | Oncology | Biosimilar | |||||||
| Pegfilgrastim | Oncology | Biosimilar | |||||||
| Follitropin alpha (FSH) | Fertility | Biosimilar | |||||||
| Insulin Aspart | Diabetes | Biosimilar | |||||||
| Insulin Glargine | Diabetes | Biosimilar | |||||||
| Insulin Lispro | Diabetes | Biosimilar | |||||||
No products match the selected filters.
Product selection and timing reflect current planning assumptions. The pipeline includes products expected to be supplied through exclusive license arrangements with affiliated entities; such arrangements are subject to execution of definitive agreements where not yet finalized. Product inclusion and timing represent target expectations only and remain subject to change.
- Benlysta belimumab
- Actemra tocilizumab
- Enbrel etanercept
- Remicade infliximab
- Cosentyx secukinumab
- Tremfya guselkumab
- Entyvio vedolizumab
- Skyrizi risankizumab
- Taltz ixekizumab
- Dupixent dupilumab
- Trulicity dulaglutide
- FSH follitropin alpha
- Repatha evolocumab
- Activase alteplase
- Neupogen filgrastim
- Avastin bevacizumab
- Opdivo nivolumab
- Neulasta pegfilgrastim
- Xgeva denosumab
- Herceptin trastuzumab
- Tecentriq atezolizumab
- Tecentriq Hybreza atezolizumab + hyaluronidase
- Trodelvy sacituzumab govitecan
- Keytruda pembrolizumab
- Keytruda Qlex pembrolizumab + berahyaluronidase alfa-pmph
- Enhertu trastuzumab deruxtecan
- Opdivo Qvantig nivolumab + hyaluronidase
- Darzalex Faspro daratumumab + hyaluronidase
- Herceptin Hylecta trastuzumab + hyaluronidase
Our Products
Recent Launches
Life at Meitheal
Join the Meitheal team! Our progressive, innovative culture embraces ambition, diversity, originality and the power of a team connection. A welcoming, respectful and engaging environment with opportunities for all, Meitheal makes and lives by decisions based on integrity, transparency and speed.
We are proud to announce we were just ranked among Crain’s 100 Best Places to Work in Chicago! We strive to make Meitheal a place of growth and inspiration where employees look forward to going to work, are recognized for their contributions and are proud to be part of our great team.
Partnerships are important to our success
Connect with us to discuss new opportunities.
